Some of the Earliest Market Access Decisions Don't Look Like Market Access Decisions

Some of the decisions that will shape a product's access are made before anyone is looking at them through the payer's eyes. They happen inside a forecast, a trial design, a distribution plan or a launch timeline, and nobody calls them market access decisions.

By the time a market access leader arrives, some consequential choices may already be difficult to change. Changing them means reopening work that other teams consider finished.

This article walks through five decisions that tend to get made this way, why each one matters to payers, and what a company can do while there are still options.

Five decisions, and what they really are

Each row below shows how the decision is usually framed inside the company, and the market access question underneath it.

Decision	How it is usually framed	The market access question underneath
Price	A forecast assumption	What will payers accept, and what net price do the benefit design and channel mix actually produce?
Evidence	A clinical-development decision	Will the endpoints, comparators and populations support the payer value story and coverage criteria?
Channel	A distribution decision	Which benefit does the product sit under, and who carries the reimbursement and cash-flow risk?
Site of care	A launch-planning decision	Where the product is administered changes who pays, how, and at what rate.
Coding	A reimbursement question left for later	Do coding, coverage and payment line up, or are they being treated as one decision when they are three?

How each one goes wrong

Price

A price enters the forecast early and gets treated as settled. If nobody tested it against payer willingness to pay, benefit design or channel mix, the net price can land below the model, and the revenue forecast built on it moves with it.

Evidence

Trial design is locked long before payers see the data. Endpoints, comparators and patient populations chosen for regulatory success may not answer the questions payers will ask, and adding evidence later is slow and expensive.

Channel

Distribution looks like an operational choice. In practice it determines which benefit the product falls under, which payers manage it, and what the reimbursement path looks like for providers and patients.

Site of care

Where a product is administered gets settled in launch planning. It changes the economics for providers and the payment rules that apply, so a choice made for convenience can create a payment problem later.

Coding

Coding is often deferred as a reimbursement detail. Coding, coverage and payment are three separate decisions, and treating them as one is how a product can launch without a clear path to being paid for.

Why the gap exists

The cause is rarely carelessness. A company 12 to 36 months from launch may not have built a market access function yet. In other organizations, the leadership seat is open because of a vacancy or transition. Either way, decisions still have to be made, so they get made by the people in the room: finance, clinical, commercial and supply chain.

The challenge is that companies may need senior market access judgment before they are ready to make a permanent hire. A full search takes time, and the decisions do not wait for it.

What to do while there are still options

You do not need a full team to start. These five checks can be done early, ideally with a market access leader's input, whether that person is a permanent hire, a fractional leader or an interim.

• Test the price assumption against payer willingness to pay, benefit design and channel mix before it hardens in the forecast.
• Review the evidence plan with a payer lens: do the endpoints, comparators and populations support coverage?
• Decide the benefit and channel on purpose, and note who carries the reimbursement risk under each.
• Map how the site of care affects who pays and how, before launch planning locks it in.
• Treat coding, coverage and payment as three decisions, each with an owner and a timeline.

Make the decisions while there are still options

Many companies have already made some of their most important market access decisions without realizing it. The earlier those decisions get a market access perspective, the more choices remain open. For more on timing, read why market access decisions come before launch.

If you're making these decisions now and want an experienced market access perspective while options are still open, I'm always glad to compare notes.

Book a call

Pre-commercial strategyFractional & interim leadershipWhy timing matters